Client & Alumni News

FDA Authorizes OraSure InteliSwab COVID-19 Rapid Tests for OTC, Single-Use, At-Home Testing 

OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced that the Emergency Use Authorization for its InteliSwab™ COVID-19 rapid tests has been amended by the U.S. Food and Drug Administration (FDA) to only require one test for individuals with symptoms of COVID-19. Previously, the at-home test was authorized for over-the-counter use in people with or without symptoms when tested twice with at least 24 hours but not more than 36 hours between tests, which is called serial testing. Now, people with symptoms only need to test once; people without symptoms should still perform serial testing if they get a negative result on their first test. Read more. Via Lehigh Valley Business, WFMZ TV-69